Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT02054104
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT02037165
- Locations
- 🇩🇪
1320.3.1 Boehringer Ingelheim Investigational Site, Dornach, Germany
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
- Conditions
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2024-02-09
- Target Recruit Count
- 30
- Registration Number
- NCT02030964
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇦🇺Sydney Childrens Hospital KCC, Randwick, Australia
🇺🇸Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
A Study of LY3127760 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT01968070
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
- Conditions
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 150
- Registration Number
- NCT01934933
- Locations
- 🇨🇳
Rheumatology Department, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 10
- Registration Number
- NCT01901679
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
Window of Opportunity Study Targeting the Inflammatory Milieu
- Conditions
- Interventions
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 42
- Registration Number
- NCT01881048
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Celecoxib Japan Observational Study for the Patients With Acute Pain
- Conditions
- Interventions
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 784
- Registration Number
- NCT01876121
A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 124
- Registration Number
- NCT01872910
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States
NSAID Treatment in Knee Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- University of Catanzaro
- Target Recruit Count
- 90
- Registration Number
- NCT01860833
- Locations
- 🇮🇹
Department of Orthopedic and Trauma Surgery, Catanzaro, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.